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Abstract
Background: The del1518 (rs3730485) polymorphism is an in/del variant in the MDM2 promoter P1. The variant is
in complete linkage disequilibrium with MDM2 SNP309 (rs2279744) and has previously been found associated with
an increased risk of colon cancer. In this study we assessed the impact of MDM2 del1518 on risk of ovarian and
endometrial cancer.
Methods: Here, we genotyped del1518 in two large hospital-based series of patients diagnosed with ovarian
(n = 1,385) or endometrial (n = 1,404) cancer and performed risk estimations as compared to the genotype
distribution among 1,872 healthy female controls.
Results: In overall analysis we observed no association between del1518 and risk of either ovarian or endometrial
cancer. However, stratifying according to SNP309 status, we found the del1518 variant to be associated with a
reduced risk of endometrial cancer among individuals carrying the SNP309TT genotype both in the dominant
(OR = 0.64; 95% CI = 0.45 – 0.90) and the recessive model (OR = 0.80; 95% CI = 0.65 – 1.00). No such association was
observed for ovarian cancer risk.
Conclusion: We found the MDM2 del1518 del variant to be associated with reduced risk of endometrial cancer
among individuals carrying the MDM2 SNP309TT genotype.
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Background
The protein product of the Mouse Double Minute 2
homolog (MDM2) gene is one of the main regulators of
the tumor suppressor p53. MDM2 inhibits p53, not only
by direct binding, but also by directing it to proteasomal
degradation. p53, on the other hand, induces MDM2
transcription in response to genotoxic stress [1–5].
Increased levels of MDM2, through mechanisms such as
gene amplification, increased transcription and elevated
translation has been observed in several human cancers
[6–8], and MDM2 overexpression has been suggested to
be an alternative mechanism of p53 inactivation and
tumor promotion [8, 9].
Over the last decade, single nucleotide polymorphisms
(SNPs) in the MDM2 promoter regions have been
reported to affect MDM2 transcription [10–12]. The
most studied MDM2 SNP, SNP309T > G (rs2279744)
was found to increase the binding affinity between the
MDM2 promoter 2 region and the transcription factor
Sp1 (specificity protein 1), resulting in increased MDM2
mRNA and protein levels [10]. While initial reports
indicated the SNP309G allele to be associated with
enhanced risk and early diagnoses of several tumor forms,
subsequent data have been at conflict, indicating potential
gender as well as ethnic differences [13–20]. A potential
reason for these findings may be interaction with other
SNP variants located in the MDM2 promoter areas.
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Previously, we and others reported a novel MDM2
SNP located 24 base pairs upstream from SNP309;
SNP285G > C (rs117039649) that also affect Sp1 binding
to the MDM2 promoter [11, 21, 22]. Notably, this SNP
was found to be differentially distributed across different
ethnic groups [11, 23].
Contrasting SNP309 and SNP285, which both are lo-
cated in the MDM2 promoter P2, the 40 bps insertion/
deletion polymorphism del1518 (rs3730485) is located in
the MDM2 promoter P1. The del1518 variant has been
reported to be in linkage disequilibrium (LD) with
SNP309, forming a SNP309T/del1518 del haplotype
[24, 25]. While the del variant has been associated with
decreased MDM2 expression [12], results so far have
linked the del1518 del allele to an increased risk of hepa-
tocellular carcinoma, colon cancer and uterine leiomyoma
[25–27] but with no associations to epithelial ovarian can-
cer, esophageal squamous cell carcinoma, breast, lung or
prostate cancer risk [24, 25, 28–30].
In the present study we assessed the potential
association between del1518 and risk for ovarian and
endometrial cancer in large hospital based sample sets,
previously genotyped for SNP309 and SNP285, enabling




All cases included in this case–control study were
obtained from hospital-based cohorts of Norwegian pa-
tients of whom the great majority were Caucasians diag-
nosed with endometrial (n = 1,404) and ovarian cancer
(n = 1,385) described in detail previously [31]. For
comparison, we used the previously reported genotypes
of the female fraction (n = 1,872) from a sample set of
3,749 healthy Norwegian individuals [32]. These individ-
uals were initially drawn from the population based
Cohort of Norway (CONOR) study [33].
For the endometrial cancer samples we had histo-
logical status for 1,320 and for the ovarian cancer sam-
ples histopathological status was available for 1,071 [31].
MDM2 genotyping
All samples were genotyped for MDM2 del1518 by using
DNA extracted from white blood cells as previously
described [25]. Briefly, the region of MDM2 containing
the del1518 indel polymorphism was amplified by
PCR, and the insertion and deletion alleles were
separated and visualized by electrophoresis in a 3%
agarose gel pre-stained with GelRed™ Nucleic Acid
Gel Stain (BIOTIUM).
MDM2 SNP309 genotypes were extracted from previously
published data from the same individuals [11, 21, 25, 31, 32].
Statistical analysis
Since we, and others, previously have shown the MDM2
del1518 to be in strong linkage disequilibrium with the
MDM2 SNP309 (the del1518 del-allele being linked to
the SNP309T-allele) [24, 25], we followed an analysis
plan specified up-front of statistical assessments. First
we performed overall risk assessments including all EC
and OC patients. Then we performed sub-analyses,
stratifying the data according to histology and according
to SNP309-status before assessing putative associations
between del1518 and cancer risk.
Possible associations between del1518 and cancer risk,
both in total and in stratified groups, were evaluated by
Odds Ratios (OR) and Fisher’s exact tests. ORs are given
with 95% confidence intervals (CI), and p-values are
given as two-sided. P-values from Fisher’s exact tests are
given as two-sided and cumulative.
All statistical analyses were performed using the IBM
SPSS statistics (version 22) software package.
Results
Distribution of del1518
The genotype distribution of the del1518 ins/del vari-
ant among the healthy controls was found to be in
Hardy-Weinberg equilibrium (p > 0.8), with a minor
allele frequency (MAF) of 0.43 (genotypes: del1518
ins/ins = 34.0%; del1518 ins/del = 46.9% and del1519
del/del = 19.2%).
An overview of the del1518 genotype distribution in
the healthy controls and the two cancer types are sum-
marized in Table 1. Among the healthy controls, the
del1518 del allele was observed in individuals carrying
the SNP309TT and 309TG genotypes only. Amongst the
patients we found one ovarian cancer patient harboring
the del1518 del/del – SNP309TG genotype and two
patients (one diagnosed with endometrial- and one
diagnosed with ovarian cancer) harboring the del1518
ins/del – SNP309GG genotype. Thus, del1518 was found
to be in strong linkage disequilibrium (LD) with SNP309
(D’ = 0.997 for endometrial cancer cases and D’ = 0.994
for ovarian cancer cases) across all groups of individuals.
Given that the SNP285C-variant is linked to the
SNP309G-allele, we here, in line with previous observa-
tions [25], found no evidence of alleles carrying both
SNP285C and del1518 del.
MDM2 del1518 and risk of endometrial – and ovarian
cancer
In order to evaluate the potential impact of MDM2
del1518 status on endometrial and ovarian cancer risk,
we evaluated the OR by comparing the frequency of the
MDM2 del1518 genotypes observed in ovarian and
endometrial cancer cases to the SNP status among the
1,872 healthy female controls. No significant association
Gansmo et al. BMC Cancer  (2017) 17:97 Page 2 of 6
between MDM2 del1518 and risk of either of the two
cancer types was found whether applying the dominant
or the recessive model (Table 1; Fig. 1a and b).
Next, we stratified the endometrial malignant le-
sions and ovarian cancers into histological subgroups
(endometrioid, adenosquamous, clear cell, serous papil-
lary, hyperplasia, carcinosarcoma and undifferentiated/
other types endometrial cancer; high-grade serous ovar-
ian cancer [HGSOC], low-grade ovarian cancer
[LGSOC], clear cell ovarian cancer, endometrioid ovar-
ian cancer and mucinous ovarian cancer). No associa-
tions between MDM2 del1518 ins/del distribution and
cancer risk were observed in either of these subgroups
(Additional file 1: Tables S1 and Additional file 2: Table
S2).
Impact of MDM2 del1518 status within SNP309 genotype
subgroups
Given that the MDM2 del1518 del allele and the
SNP309T was found to be in strong LD forming a distinct
del1518del/SNP309T haplotype, we performed refined
analyses, restricting our OR estimates to individuals carry-
ing the SNP309TT or SNP309TG genotypes. Within the
subgroup of individuals carrying the SNP309TT genotype,
we observed an association between the del1518 del allele
and a reduced risk of endometrial cancer, both when ap-
plying the dominant (OR = 0.64, CI = 0.45 – 0.90) and the
recessive model (OR = 0.80, CI = 0.65 – 1.00; Table 2;
Fig. 1a and b). In contrast, no significant association was
observed among the ovarian cancer patients. Among indi-
viduals harboring the SNP309TG genotype, no association
to cancer risk was recorded in either of the two cancer
forms (Table 3).
The majority of the endometrial cancer patients had
tumors of endometroid histology. Within this subgroup
(endometroid histology and SNP309TT-genotype), we
found the del1518 del allele to be associated with reduced
cancer risk, similar to the reduction observed for the total
EC-sample set (OR = 0.64, CI = 0.44 – 0.92; dominant
model; Additional file 3: Table S3). Regarding the other
histology subgroups, these were too small for formal
statistical risk analysis among individuals harboring the
Table 1 MDM2 del1518 distribution and cancer risk (OR)
Cases/controls Genotype del1518 n (%) OR (95% CI) del1518 Fisher exact OR (95% CI) del1518 Fisher exact
ins/ins ins/del del/del Dominant modela Recessive modelb
Healthy Controls 636 (34.0) 877 (46.9) 359 (19.2) 1.00 - 1.00 -
Ovarian cancer 484 (35.0) 655 (47.3) 246 (17.7) 0.96 (0.83–1.11) 0.576 0.91 (0.76–1.09) 0.316
Endometrial cancer 492 (35.0) 664 (47.3) 248 (17.7) 0.95 (0.83–1.10) 0.528 0.90 (0.76–1.08) 0.276
adel/del + ins/del versus ins/ins
bdel/del versus ins/del + ins/ins
Fig. 1 MDM2 del1518 and impact on risk of ovarian and endometrial cancer. Forest plots showing the impact of MDM2 del1518, in the total
sample sets, and within the subgroup of SNP309, on ovarian (OC) and endometrial (EC) cancer risk. a dominant model and b recessive model
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SNP309TT genotype (pooled data for these subgroups
shown in Additional file 3: Table S3).
Discussion
Previous studies have revealed MDM2 promoter P2 SNP
variants like SNP309T > G and SNP285G > C to modu-
late gene transcription and affect cancer risk [10, 11].
In the present study, we explored the impact of a third
MDM2 polymorphism, del1518 ins/del, located in pro-
moter P1, on the risk of endometrial and ovarian cancer
in a Caucasian population. Similar to what has been pre-
viously reported in Han Chinese [24], we confirmed
del1518del/ins to be in strong linkage disequilibrium
with the SNP309, forming a distinct MDM2 del1518del/
SNP309T haplotype [24, 25] with a MAF different from
Chinese (MAF = 0.30) [24].
We did not detect an effect of del1518 status on the risk
of endometrial or ovarian cancer in the general popula-
tion. Howevver, based on previous findings indicating
different MDM2 promoter SNPs may act in concert [11]
we performed subgroup analyses stratifying individuals
with respect to SNP309 genotypes. (Linkage disequilib-
rium precluded assessment of SNP285 subgroups since all
SNP285C-alleles are linked to SNP309G-alleles while
del1518 del locates to the SNP309T-allele [23]).
Doing so, we found the del1518 del- allele to be asso-
ciated with a reduced risk of endometrial but not for
ovarian cancer applying a dominant as well as recessive
model among individuals harboring the SNP309TT
genotype (risk reduction of 36% and 20%, respectively).
This finding is in line with previous in vitro luciferase
gene reporter assay findings, showing the presence of
the del1518 del allele to result in complete abrogation of
promoter activity [12]. Lack of effect on ovarian cancer
risk is also in accordance with the results from a
previous study performed in Chinese individuals [28].
However, other studies have found the del1518 del allele
to confer an increased risk for other cancer forms like
hepatocellular carcinomas [26] and left sided colon can-
cer among individuals carrying the SNP309TG genotype
[25], as well as increased risk for uterine leiomyomas
(non-cancerous growths in the uterus) [27], but no
associations to epithelial ovarian cancer, esophageal
squamous cell carcinoma, breast, lung or prostate cancer
risk [24, 25, 28–30]. Taken together, these findings sug-
gests the del 1518 ins/del variant may have different ef-
fects on risk for cancer development in different organs,
partly dependent on interactions with other MDM2 SNP
variants, similar to what has been observed for
promoter variants like SNP309 and SNP285 [11, 17,
21, 32]. Interestingly, both endometrial and ovarian can-
cer risk has previously been found to be reduced by the
SNP285C-allele [11, 21]. Further, the SNP309G-allele has
been found to be associated with an increased but also a
reduced cancer risk across different tissues [16, 18, 34,
35]. Also the fact that mice carrying the human MDM2
SNP309G allele only displayed elevated MDM2 expression
in a few tissues [36] supports the hypothesis that SNP309
may act as a cancer risk factor in distinct tissues only.
Thus, our observation of del1518 del variant reducing the
risk of endometrial but not ovarian cancer may indicate
that this variant is modulating the binding of transcription
factors that are differentially expressed in these two
tissues.
Given that we previously have found a SNP in the
MDM4 3 ‘UTR (SNP34091) to be associated with in-
creased risk of serous, and in particular high grade ser-
ous ovarian cancer [31], we performed subgroup analysis
based on histology status with respect to del1581. These
subgroup analyses did not reveal any histology specific
effects of del1518 status, indicating that this variant have
no effect on tumor progression.
Table 2 MDM2 del1518 among SNP309TT
Cases/controls Genotype del1518 n (%) OR (95% CI) del1518 Fisher exact OR (95% CI) del1518 Fisher exact
ins/ins ins/del del/del Dominant modela Recessive modelb
Healthy Controls 70 (9.5) 311 (42.0) 359 (48.5) 1.00 - 1.00
Ovarian cancer 64 (11.6) 242 (44.0) 245 (44.5) 0.80 (0.56–1.14) 0.231 0.85 (0.68–1.06) 0.159
Endometrial cancer 81 (14.1) 247 (42.9) 248 (43.1) 0.64 (0.45–0.90) 0.011 0.80 (0.65–1.00) 0.051
adel/del + ins/del versus ins/ins
bdel/del versus ins/del + ins/ins
Table 3 MDM2 del1518 among SNP309TG
Cases/controls Genotype del1518 n (%) OR (95% CI) del1518 Fisher exact
ins/ins ins/del del/dela Ins/del vs. ins/ins
Healthy Controls 312 (35.5) 566 (64.5) - 1.00 -
Ovarian cancer 213 (34.1) 412 (65.9) - 1.07 (0.86–1.32) 0.583
Endometrial cancer 226 (35.2) 416 (64.8) - 1.02 (0.82–1.26) 0.914
aNo observations since del1518 del is linked to SNP309T
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Conclusion
In conclusion we find the MDM2 SNP del1518 del vari-
ant to be associated with reduced risk of endometrial
cancer among individuals carrying the SNP309TT
genotype, an observation warranting confirmation in
independent studies.
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